Bill > S3129

This bill establishes and modifies several requirements to address prescription drug prices under Medicare. The bill generally limits payment amounts for drugs and biologics under Medicare medical services, reduces cost-sharing under the Medicare prescription drug benefit, and establishes several reporting requirements for drug manufacturers with respect to drug prices. Some key provisions include: - Requiring manufacturers of certain single-dose container or single-use package drugs payable under Part B to provide refunds for discarded amounts of such drugs - Providing for variation in payment for certain drugs covered under Part B based on per beneficiary allowed charges - Establishing a maximum add-on payment amount for drugs and biologicals under Part B - Redesigning the Medicare Part D benefit structure, including reducing the reinsurance payment amount and establishing a manufacturer discount program - Requiring prescription drug plan sponsors to include real-time benefit information as part of their electronic prescription program - Requiring prescription drug plans and MAPD plans to report potential fraud, waste, and abuse to the Secretary of HHS - Establishing pharmacy quality measures under Medicare Part D - Requiring reporting on drug price increases and public disclosure of certain drug pricing information - Providing the Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission with access to certain drug payment and rebate information.

Budget and Finance

https://www.congress.gov/bill/116th-congress/senate-bill/3129/all-info